4 August 2017 (Friday) - ASH Update



The ASH people sent news and updates from the haematology/oncology community with some highlights of this week’s developments:

NEWS
FDA Announces Plans to Advance Digital Health Care
The U.S. Food and Drug Administration has announced a pilot program allowing medical software companies to “pre-certify” for marketing digital devices and products.
Eculizumab Associated With Increased Risk of Meningococcal Disease
A report from the Centers for Disease Control and Prevention, noted that eculizumab – an FDA-approved drug for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome – is associated with a 1,000- to 2,000-fold risk of meningococcal disease. 
PERSPECTIVES
Carfilzomib Combination Has Manageable Toxicity in Patients With Newly Diagnosed MM
CHAMPION-2 researchers found that carfilzomib plus cyclophosphamide and dexamethasone is a safe option for patients with newly diagnosed multiple myeloma; the combination was associated with a high response rate.

No comments:

Post a Comment